Kentera was approved through the centralized procedure by the EMEA in 2004 and has been on the market in a number of countries with current sales of over E7 million.
Giovanni Recordati, chairman and CEO of Recordati, said: “The acquisition of Kentera, an original system for the administration of a well-known drug improving its tolerability profile, reinforces Recordati’s focus in the urology area where it is developing silodosin, indicated for the treatment of benign prostate hypertrophy, due for filing in Europe in the second half of 2008.”